Dova Pharmaceuticals (NASDAQ:DOVA) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Wednesday, BidAskClub reports.

DOVA has been the subject of several other research reports. HC Wainwright set a $18.00 target price on shares of Dova Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 5th. Wedbush started coverage on shares of Dova Pharmaceuticals in a research note on Wednesday, May 22nd. They issued an “outperform” rating and a $19.00 target price for the company. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $28.25.

Shares of NASDAQ DOVA traded down $0.07 during mid-day trading on Wednesday, hitting $9.17. The company had a trading volume of 173,783 shares, compared to its average volume of 163,637. The company has a debt-to-equity ratio of 0.20, a quick ratio of 4.27 and a current ratio of 4.46. Dova Pharmaceuticals has a 12 month low of $5.62 and a 12 month high of $35.33. The stock has a market cap of $254.38 million, a PE ratio of -3.53 and a beta of 1.80.

Dova Pharmaceuticals (NASDAQ:DOVA) last released its earnings results on Tuesday, May 7th. The company reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.10. Dova Pharmaceuticals had a negative net margin of 521.67% and a negative return on equity of 87.20%. The business had revenue of $4.00 million during the quarter, compared to analysts’ expectations of $3.46 million. Research analysts forecast that Dova Pharmaceuticals will post -2.03 earnings per share for the current fiscal year.

In other Dova Pharmaceuticals news, Director Paul B. Manning purchased 68,000 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was purchased at an average price of $7.48 per share, with a total value of $508,640.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 60.30% of the company’s stock.

Large investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. raised its position in Dova Pharmaceuticals by 14,705.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock worth $38,000 after purchasing an additional 5,000 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in Dova Pharmaceuticals by 22.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 13,300 shares of the company’s stock worth $336,000 after purchasing an additional 2,400 shares in the last quarter. Rhumbline Advisers raised its position in Dova Pharmaceuticals by 46.1% in the fourth quarter. Rhumbline Advisers now owns 15,343 shares of the company’s stock worth $116,000 after purchasing an additional 4,843 shares in the last quarter. State of Wisconsin Investment Board raised its position in Dova Pharmaceuticals by 29.3% in the first quarter. State of Wisconsin Investment Board now owns 15,900 shares of the company’s stock worth $141,000 after purchasing an additional 3,600 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new position in Dova Pharmaceuticals in the fourth quarter worth about $136,000. 30.18% of the stock is owned by hedge funds and other institutional investors.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Read More: Bond

Analyst Recommendations for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.